Metabolic Research Peptides
This category covers GLP-1 receptor agonists and related incretin-class compounds used extensively in metabolic biology research. All compounds are supplied for qualified in vitro laboratory research use only — not as pharmaceuticals or for therapeutic administration.

The GLP-1 class has become one of the most studied groups in contemporary peptide research, driven by interest in metabolic signalling pathways, energy homeostasis, and incretin biology. Key compounds in this category include:

Semaglutide — GLP-1R monoagonist; extensively characterized in clinical and preclinical metabolic research
Tirzepatide — Dual GIP/GLP-1R agonist (“twincretin”); studied for expanded receptor targeting compared to semaglutide
Retatrutide — Triple GIP/GLP-1R/GCGR agonist; active Phase II/III clinical investigation
Cagrilintide — Long-acting amylin analogue; studied in combination with semaglutide in research protocols
AOD9604 — Modified GH fragment investigated in lipolysis research

Research using these compounds typically focuses on receptor binding assays, downstream cAMP signalling, in vitro cell line metabolic studies, and rodent model experiments examining energy balance and metabolic markers. All are ≥98% purity, third-party HPLC and MS verified.

All compounds sold strictly for laboratory research. Not for human or animal administration. Not evaluated by Health Canada for therapeutic use.